IFW Reference Manager

Application Number: [ ] Submit

Application Number 10/716,098

Testing 510903 - Form PTO-1449, 17-NOV-2003, Paper Number 20031117

Document Number	Date	Inventor Names	Classification
US-3,800,039	03-1974	Marquis et al.	514/266.1
US-4,139,561	02-1979	Onopchenko et al.	564/423
US-4,216,341	08-1980	Onopchenko et al.	564/418
US-4,219,679	08-1980	Onopchenko et al.	568/705
US-4,255,313	03-1981	Antonoplos et al.	524/104
US-4,281,127	07-1981	LeMahieu et al.	544/287
US-4,305,751	12-1981	Sabourin et al.	504/330
US-4,322,420	03-1982	Kobayashi et al.	514/266.4
US-4,943,533	07-1990	Mendelsohn et al.	530/388.22
US-5,089,499	02-1992	Barker et al.	514/266.3
US-5,214,144	05-1993	Tai et al.	544/283
US-5,256,781	10-1993	Primeau et al.	544/293
US-5,457,105	10-1995	Barker, Andrew J.	514/234.5
US-5,475,001	12-1995	Barker, Andrew J.	514/183
US-5,580,870	12-1996	Barker et al.	514/234.5
US-5,616,582	04-1997	Barker, Andrew J.	514/234.5
US-5,639,881	06-1997	Skibo et al.	544/251
US-5,654,307	08-1997	Bridges et al.	514/264.11
US-5,686,458	11-1997	Lee et al.	514/266.21
US-5,707,992	01-1998	Webber et al.	514/252.02
US-5,710,145	01-1998	Engel et al.	514/183
US-5,747,498	05-1998	Schnur et al.	514/266.4
US-5,770,195	06-1998	Hudziak et al.	424/130.1
US-5,817,674	10-1998	Clemence et al.	514/311
US-5,821,246	10-1998	Brown et al.	514/252.17
US-5,948,784	09-1999	Fujiwara et al.	514/266.2
US-6,004,967	12-1999	McMahon et al.	514/266.4
US-6,004,979	12-1999	Clemence et al.	514/312
US-6,130,218	10-2000	Morsdorf et al.	514/252.17
US-6,169,091	01-2001	Cockerill et al.	514/228.2
US-6,476,040	11-2002	Norris et al.	514/266.4

EAST Search String:

("3800039"|"4139561"|"4216341"|"4219679"|"4255313"|"4281127"|"4305751"|"4322420"|"4943533"|"5

10/716,098

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	540	((514/266.4) or (544/293)).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2006/09/19 15:06
L2	109	L1 and ethynyl	US-PGPUB; USPAT	OR	OFF	2006/09/19 15:07
L3	28	L2 and mesylate	US-PGPUB; USPAT	OR	OFF	2006/09/19 15:07

10/ 716,098

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:47:29 ON 19 SEP 2006

=> file reg

10/ 716,098

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:47:44 ON 19 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2006 HIGHEST RN 907539-37-1
DICTIONARY FILE UPDATES: 18 SEP 2006 HIGHEST RN 907539-37-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10716098.str



chain nodes :
11 18 19 20 21 22 23 24 25 26 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
chain bonds :
5-21 6-20 7-11 11-12 16-18 18-19 20-22 21-24 22-23 23-26 24-25 25-27 26-28 27-29
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
5-21 6-20 7-11 11-12 20-22 21-24 23-26 25-27 26-28 27-29
exact bonds :
16-18 18-19 22-23 24-25

normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
isolated ring systems :
containing 1 : 12 :

Hydrogen count :
9:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:48:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 357 TO ITERATE

100.0% PROCESSED 357 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.01

L2 33 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'HCAPLUS' ENTERED AT 14:48:10 ON 19 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10/ 716,098

FILE COVERS 1907 - 19 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 18 Sep 2006 (20060918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l2
L3          439 L2

=> d his

     (FILE 'HOME' ENTERED AT 14:47:29 ON 19 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 14:47:44 ON 19 SEP 2006
L1               STRUCTURE UPLOADED
L2            33 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 14:48:10 ON 19 SEP 2006
L3            439 S L2

=> s l3 and mesylate
           6686 MESYLATE
L4            35 L3 AND MESYLATE

=> d his

     (FILE 'HOME' ENTERED AT 14:47:29 ON 19 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 14:47:44 ON 19 SEP 2006
L1               STRUCTURE UPLOADED
L2            33 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 14:48:10 ON 19 SEP 2006
L3            439 S L2
L4             35 S L3 AND MESYLATE

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 35 ANSWERS - CONTINUE? Y/(N):y
```

L4 ANSWER 1 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:891362 HCAPLUS
TITLE: Anticancer sustained-release implant
INVENTOR(S): Sun, Juan; Sun, Zhonghou; Kong, Qingxin; Tian, Shaolan
PATENT ASSIGNEE(S): Jinan Kangquan Medical Science and Technology Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 26pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1824318	A	20060830	CN 2005-10200848	20051220

PRIORITY APPLN. INFO.: CN 2005-10200848 20051220

AB The invention provides an anticancer sustained-release implant comprising an anticancer active ingredient and a pharmaceutically-acceptable adjuvant ingredient. The active ingredient includes an angiogenesis inhibitor and/or a hormonal anticancer drug, wherein the adjuvant ingredient is a biocompatible and biodegradable polymer. This anticancer implant allows the sustained release of active ingredient in local tumor site, which reduces greatly systemic toxicity and results in a high local drug level. Because the implant can not only efficiently kill tumor cells but selectively damage the tumor vessels, it can be used alone or combined with nonoperative therapy to enhance their therapeutic effects.

IT INDEXING IN PROGRESS
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticancer sustained-release implant)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:790907 HCAPLUS
DOCUMENT NUMBER: 145:202856
TITLE: Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
INVENTOR(S): Zeligs, Michael A.
PATENT ASSIGNEE(S): Bioresponse LLC, USA
SOURCE: PCT Int. Appl., 77pp. CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006083458	A2	20060810	WO 2005-US47537	20051230

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-640301P P 20041230

AB The present invention includes compns. and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3'-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV.

IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of diindolylmethane-related indoles for treatment and prevention of respiratory syncytial virus-associated conditions and combination with epidermal growth factor receptor inhibitors and other agents)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 3 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:733281 HCAPLUS
DOCUMENT NUMBER: 145:188868
TITLE: Preparation of pyrazolecarboxamides for use in combination with a cytotoxic compound or signalling inhibitor
INVENTOR(S): Curry, Jayne Elizabeth; Lyons, John Francis; Squires, Matthew Simon; Thompson, Neil Thomas; Thompson, Kyla Merriom; Wyatt, Paul Graham
PATENT ASSIGNEE(S): Astex Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 247 pp. CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006077424	A1	20060727	WO 2006-GB204	20060120

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:
US 2005-645975P P 20050121
US 2005-645976P P 20050121
US 2005-645986P P 20050121
US 2005-645987P P 20050121
US 2005-646113P P 20050121

GI



I

AB The invention provides a combination of a cytotoxic compound or signaling inhibitor and a compound I [X = R1AR4- or a 5-6 membered carbocyclic or heterocyclic ring; A = a bond, SO2, C(O), NR9C(O) or OC(O) (wherein R9 = H or hydrocarbyl optionally substituted by hydroxy or alkoxy); Y = a bond or an alkylene; R1 = H, a carbocyclic or heterocyclic group, or (un)substituted hydrocarbyl; R2 = H, halo, alkoxy (e.g. methoxy), (un)substituted hydrocarbyl; R3 = H, carbocyclic and heterocyclic groups; R4 = H or (un)substituted hydrocarbyl; or salts or tautomers or N-oxides or solvates thereof]. Over two-hundred compds. I were prepared E.g., a 3-step synthesis of 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic

L4 ANSWER 3 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
acid piperidin-4-ylamide (II), starting from 2,6-dichlorobenzoyl chloride and Me 4-amino-1H-pyrazole-3-carboxylate, was given. The biol. activities of compds. I as inhibitors of CDK kinases, GSK-3 kinase and inhibitors of cell growth were demonstrated (data given). The effect of II in combination with various other therapeutic agents was assesed (data given).
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of pyrazolecarboxamides for use in combination with cytotoxic
compound or signaling inhibitor for treating and preventing diseases)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:681476 HCAPLUS
DOCUMENT NUMBER: 145:123040
TITLE: Anti-CRIPTO antibodies or CRIPTO-binding molecules and conjugates for treating cancer
INVENTOR(S): Glaser, Scott; Van Vlijmen, Herman; Lugovskoy, Alexey Alexandrovich; Sanicola-Nadel, Michele; Wu, Xiufeng; Garber, Ellen
PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA
SOURCE: PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074397	A2	20060713	WO 2006-US502	20060105

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-641691P P 20050105
AB The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.
IT 183319-69-9, Erlotinib hydrochloride
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-CRIPTO antibodies or CRIPTO-binding mols. and conjugates for treating cancer)
RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

L4 ANSWER 5 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:586483 HCAPLUS
DOCUMENT NUMBER: 145:130748
TITLE: Manufacture of drug composition containing angiogenesis inhibitor for treating tumor
INVENTOR(S): Kong, Qingzhong; Sun, Juan
PATENT ASSIGNEE(S): Shandong Lanjin Biotech Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 20 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1686546	A	20051026	CN 2005-10042264	20050406
PRIORITY APPLN. INFO.:			CN 2005-10042264	20050406

AB The title composition contains tyrosine kinase inhibitor or a combination of tyrosine kinase inhibitor and nitrosourea antitumor agent as active component and auxiliary materials. The composition can effectively destroy tumor blood vessel, inhibit neovascularization, and promote penetration and diffusion of antitumor agents into the tumor tissues, therefore decreasing the tolerance of tumor tissues to nitrosourea antitumor agents. The auxiliary materials are composed of degradable and biocompatible polymers, which can achieve the sustained-release of antitumor agents specifically to tumor tissues, therefore decreasing the drug toxicity of whole body while maintaining necessary drug concentration on tumor tissues.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of drug composition containing angiogenesis inhibitor for treating
tumor)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:408954 HCAPLUS
DOCUMENT NUMBER: 144:425724
TITLE: Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
INVENTOR(S): Zeligs, Michael A.
PATENT ASSIGNEE(S): Bioresponse LLC, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006047716	A2	20060504	WO 2005-US38862	20051026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006111423	A1	20060525	US 2005-260543	20051026
PRIORITY APPLN. INFO.:			US 2004-622333P P	20041026
OTHER SOURCE(S):			MARPAT 144:425724	

AB The invention includes compns. and methods for the treatment and prevention of conditions associated with human cytomegalovirus (HCMV) infection. HCMV-associated conditions include infections (active and latent), benign cell-proliferative conditions, pre-cancerous cell-proliferative conditions, and cancerous conditions. In particular, the invention describes therapeutic and preventative uses for 3,3'-diindolylmethane (DIM), or a DIM-related indole, in combination with an inhibitor of a membrane-bound growth factor receptor (GFR), to treat conditions associated with exposure to HCMV. In certain embodiments, the compns. of the invention can be used in combination with radiation therapy.

IT 183321-74-6, Erlotinib 884844-52-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diindolylmethane-related indoles and growth factor receptor inhibitors for treatment of human cytomegalovirus-associated disease)

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 884844-52-4 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, mixt. with 3,3'-methylenebis[1H-indole] (9CI) (CA INDEX NAME)

CM 1

CRN 183321-74-6
CMF C22 H23 N3 O4



CM 2

CRN 1968-05-4
CMF C17 H14 N2



L4 ANSWER 6 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 7 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:372185 HCAPLUS
DOCUMENT NUMBER: 145:34048
TITLE: Anticancer implant compositions comprising vasoinhibitors
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Kong, Qingxin
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 24 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733304	A	20060215	CN 2005-10044381	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044381	20050805

AB The anticancer implant composition comprises (1) active ingredients including a vasoinhibitor, and an anticancer drug selected from the group including bischloroethylamines, paclitaxel, antibiotics, antimetabolites and combinations thereof; and (2) pharmaceutical adjuvant, a biocompatible and degradable polymer which can slowly release the anticancer drugs at the tumor site during the degradation and absorption process. The composition can be placed at the tumor site to reduce systemic toxic action of the drugs, and also selectively increase the drug level at the tumor site so as to improve the therapeutic effect of non-operative therapy such as chemotherapy and radiotherapy.

IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasoinhibitor/antitumor composite implant)

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:372184 HCAPLUS
DOCUMENT NUMBER: 145:34047
TITLE: Anticancer implant compositions containing vasoinhibitor/pyrimidine derivative composite implant
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Liu, Enxiang
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 18 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733300	A	20060215	CN 2005-10044377	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044377	20050805

AB The anticancer implant composition comprises a vasoinhibitor, an anticancer drug, and pharmaceutical adjuvant, wherein the anticancer drug is a pyrimidine analog or a derivative thereof. The adjuvant is a biocompatible and degradable polymer which can slowly release the anticancer drugs at the tumor site during the degradation and absorption process. The composition can be placed at the tumor site to reduce systemic toxic action of the drugs, and also selectively increase the drug level at the tumor site so as to improve the therapeutic effect of non-operative therapy such as chemotherapy and radiotherapy.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasoinhibitor/pyrimidine derivative antitumor composite implant)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:372183 HCAPLUS
DOCUMENT NUMBER: 145:34046
TITLE: An anticancer implant composition containing vasoinhibitor/DNA inhibitor
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Tian, Shaolan
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 19 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733305	A	20060215	CN 2005-10044382	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044382	20050805

AB The anticancer implant composition comprises (1) active ingredients including a vasoinhibitor and a DNA inhibitor selected from the group including DNA repair inhibitor, DNA-dependent protein kinase inhibitor, poly(ADP-ribose) polymerase inhibitor, and combination thereof; and (2) pharmaceutical adjuvant, a biocompatible and degradable polymer which can slowly release the anticancer drugs at the tumor site during the degradation and absorption process. The composition can be placed at the tumor site to reduce systemic toxic action of the drugs, and also selectively increase the drug level at the tumor site so as to improve the therapeutic effect of non-operative therapy such as chemotherapy and radiotherapy.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of vasoinhibitor/DNA inhibitor composite antitumor implant)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:372182 HCAPLUS
DOCUMENT NUMBER: 144:495317
TITLE: Anticancer implantation composition containing angiogenesis inhibitor and antitumor agent
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Yu, Jianjiang
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 19 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733302	A	20060215	CN 2005-10044379	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044379	20050805

AB The title anticancer implantation composition comprises an angiogenesis inhibitor, an antitumor agent (plant alkaloids, platinum compds., tetrazines, and/or topoisomerase inhibitors), and pharmaceutical auxiliary materials. The auxiliary materials are biocompatible and degradable polymer which can slowly release the anticancer medicines at the tumor site during the degradation and absorption process. This composition can be placed at the tumor site to reduce systemic toxic reaction of the drugs, to increase the drug concentration selectively at the tumor site, and to improve the therapeutic effect of non-operative therapy, such as chemotherapy and radiotherapy.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticancer implantation composition containing angiogenesis inhibitor and anticancer medicine)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:372180 HCAPLUS
DOCUMENT NUMBER: 145:34045
TITLE: Anticancer implant composition comprising vasoinhibitor and phosphoinositide kinase inhibitor
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Zhang, Jie
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733303	A	20060215	CN 2005-10044380	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044380	20050805

AB The anticancer implant composition comprises a vasoinhibitor, a phosphoinositide 3-kinase inhibitor, and pharmaceutical adjuvant. The adjuvant is biocompatible and degradable polymer which can slowly release the anticancer drugs at the tumor site during the degradation and absorption process. The composition can be placed at the tumor site to reduce systemic toxic action of the drugs, and also selectively increase the drug level at the tumor site so as to improve the therapeutic effect of non-operative therapy such as chemotherapy and radiotherapy.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticancer implant composition comprising vasoinhibitor and phosphoinositide kinase inhibitor)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:372179 HCAPLUS
DOCUMENT NUMBER: 145:34044
TITLE: Anticancer implant compositions containing vasoinhibitor/nitrogen mustard and/or antimitotic
INVENTOR(S): Kong, Qingzhong; Sun, Juan; He, Runping
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733301	A	20060215	CN 2005-10044378	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044378	20050805

AB The anticancer implant composition comprises a vasoinhibitor, an anticancer drug, and pharmaceutical adjuvant, wherein the anticancer drug is selected from nitrogen mustard compds. and/or antimitotic agents. The adjuvant is biocompatible and degradable polymer which can slowly release the anticancer drugs at the tumor site during the degradation and absorption process. The composition can be placed at the tumor site to reduce systemic toxic action of the drugs, and also selectively increase the drug level at the tumor site so as to improve the therapeutic effect of non-operative therapy such as chemotherapy and radiotherapy.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasoinhibitor/nitrogen mustard and/or antimitotic composite antitumor implant)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:316453 HCAPLUS
DOCUMENT NUMBER: 145:50869
TITLE: Implants for local antitumor treatment containing angiogenesis inhibitors and antitumor drugs and biodegradable polymers
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Sun, Zhonghou
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 18 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1736486	A	20060222	CN 2005-10044383	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044383	20050805

AB The title implant comprises antitumor active ingredients and pharmaceutical auxiliary materials, wherein the active ingredients include (1) angiogenesis inhibitors selected from thalidomide, endostatin, etc., and (2) antitumor drug of glutathione synthetase inhibitor and/or nitric oxide synthase inhibitor. The pharmaceutical auxiliary materials are biocompatible and biodegradable polymers. The implant can slowly release the antitumor drug at the local site of tumors, so as to reduce systemic toxic reaction and improve the therapeutic effect of non-operative therapy such as chemotherapy and radiotherapy.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor implants containing angiogenesis inhibitors and antitumor drugs and biodegradable polymers)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:220544 HCAPLUS
DOCUMENT NUMBER: 144:338105
TITLE: Angiostatic and guanine analog composite antitumor implanting agent
INVENTOR(S): Kong, Qingzhong; Sun, Juan; Chen, Ying
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 20 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1733306	A	20060215	CN 2005-10044376	20050805
PRIORITY APPLN. INFO.:			CN 2005-10044376	20050805

AB The antitumor implanting agent is composed of angiostatic agent 5-30, antitumor agent 5-30, and medical adjuvant to 100%. The angiostatic agent is carboxyamidotriazole, thalidomide, linomide, angiostatin, endostatin, vascular endothelial growth factor receptor inhibitor, imatinib mesylate, semaxanib, gefitinib, erlotinib, etc. The antitumor agent is guanine, O6-benzylguanine, O6-butylguanine, O6-methylguanine, O6-alkylguanine, 2-amino-6-oxypurine, O6-benzyl-2'-deoxyguanosine, 8-amino-O6-benzylguanine, 8-hydroxy-O6-benzylguanine, 8-bromo-O6-benzylguanine, etc. The medical adjuvant is polylactic acid, ethylene-vinyl acetate copolymer, xylitol, oligosaccharide, chitin, hyaluronic acid, chondroitin sulfate, etc. The dosage form of the antitumor implanting agent is suspension, release sustaining agent, implant, and release sustaining implant. The systemic toxic reaction of the antitumor agent is decreased and the local concentration of the antitumor agent is increased by local administration, so the pharmacol. effect is increased.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiostatic and guanine analog composite antitumor implanting agent)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:194233 HCAPLUS
DOCUMENT NUMBER: 144:252596
TITLE: Tumor-associated HLA-restricted proteinase 3 peptides as vaccines to treat and prevent cancers
INVENTOR(S): Molldrem, Jeffrey; Barrett, A. John
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 126 pp. CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006045883	A1	20060302	US 2004-926852	20040826
PRIORITY APPLN. INFO.:			US 2004-926852	20040826

AB The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of the target protein cells.
IT 183321-74-6, Erlotinib
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated HLA-restricted proteinase 3 peptides as vaccines to treat and prevent cancers)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:192686 HCAPLUS
DOCUMENT NUMBER: 144:252592
TITLE: Tumor-associated HLA-restricted antigen peptides as vaccines and other antitumor agents for preventing and treating cancer
INVENTOR(S): Molldrem, Jeffrey
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, USA
SOURCE: U.S. Pat. Appl. Publ., 127 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006045881	A1	20060302	US 2004-927634	20040826
PRIORITY APPLN. INFO.:			US 2004-927634	20040826

AB The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, neutrophil elastase peptides other than PR1, cyclin E1 peptides, cyclin D peptides, or cyclin E2 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack tumor cells.
IT 183321-74-6, Erlotinib
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated HLA-restricted antigen peptides as vaccines and other antitumor agents for preventing and treating cancer)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:148995 HCAPLUS
DOCUMENT NUMBER: 144:232913
TITLE: Preparation of nitrogen triheterocyclic compounds for treating cancer or viral diseases
INVENTOR(S): Attardo, Giorgio; Roulston, Anne
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 82 pp., Cont.-in-part of U.S. Ser. No. 857,458.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006035945	A1	20060216	US 2005-225452		20050913
US 2005014802	A1	20050120	US 2004-857458		20040528
PRIORITY APPLN. INFO.:			US 2003-474741P	P	20030530
			US 2004-857458	A2	20040528

OTHER SOURCE(S): MARPAT 144:232913
GI



AB The present invention relates to novel triheterocyclic compds. I [Q1 = O, S, NR1; Q2 = CR3, N; Q3 = CR5, N; Q4 = CR9, or N; R1, R3-R5, R7-R13 = independently (un)substituted C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, etc.; R2 = H, C1-8 alkyl, OH; R6 = H, halo, OH, NH2, C1-8 alkyl, C1-8 alkoxy] and pharmaceutically acceptable salts and prodrugs thereof, and methods useful for treating or preventing cancer or a neoplastic disorder

L4 ANSWER 17 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
comprising administering I. The compds., compns., and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus. Thus, reaction of 4-methoxy-3-pyrrolidin-2-one with the Vilsmeier reagent prepd. from DMF and POBr3 gave 70% pyrrolomethene II. Palladium-catalyzed coupling of II with N-tert-butoxycarbonylindole-2-boronic acid and deprotection gave indolylpyrrole III, which underwent condensation with 2,4-dimethylpyrrole to give triheterocycle IV. Phosphate prodrugs of IV are also prepd. The anticancer effects of IV tartrate salt and solubilities of IV tartrate and mesylate salts, and of a prodrug of IV are also described. The compds. of the invention can also be used in combination with other chemotherapeutic agents. For example, IV tartrate had an IC50 of 0.2μM against cervical cancer cell line C-33A (the IC50 was based on measurements of ATP levels at 72 h post-treatment compared with untreated cells).
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(addnl. therapeutic agent; preparation of nitrogen triheterocyclic compds.
for treating cancer or viral diseases)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1314363 HCAPLUS
DOCUMENT NUMBER: 144:57544
TITLE: Antibody drug conjugates and uses for cancer therapy
INVENTOR(S): Ebens, Allen J., Jr.; Jacobson, Frederic S.; Polakis, Paul; Schwall, Ralph H.; Sliwkowski, Mark X.; Spencer, Susan D.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117986	A2	20051215	WO 2005-US18829	20050531
WO 2005117986	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005276812	A1	20051215	US 2005-141344	20050531
PRIORITY APPLN. INFO.:			US 2004-576517P	P 20040601
			US 2004-616098P	P 20041005

OTHER SOURCE(S): MARPAT 144:57544
AB The present invention relates to antibody-drug conjugate compds. with a formula of Ab-(L-D)p where 1 to 8 (p) maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compds. may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
IT 183321-74-6, Erlotinib
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibody drug conjugates and uses for cancer therapy)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 19 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1311332 HCAPLUS
DOCUMENT NUMBER: 144:32190
TITLE: Use of imatinib to treat liver disorders and viral infections
INVENTOR(S): Riviere, Philippe; Riviere, Marc; Reader, Stephanie
PATENT ASSIGNEE(S): Bioniche Life Sciences Inc., Can.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117885	A1	20051215	WO 2005-CA869	20050603

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-576573P P 20040604

AB The invention relates to the use of imatinib for treating viral liver diseases and in particular for viral hepatitis. The invention provides the use of imatinib for inhibiting replication, transmission or both of hepatitis viruses. The invention further relates to the use of imatinib for inhibiting replication, transmission or both of other viruses including herpes virus, poxvirus, influenza virus, parainfluenza virus, respiratory syncytial virus, rhinovirus, yellow fever virus, west nile virus, and encephalitis virus.

IT 183319-69-9, OSI-774
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of imatinib to treat liver disorders and viral infections)

RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1290072 HCAPLUS
DOCUMENT NUMBER: 144:46998
TITLE: The X-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design
INVENTOR(S): Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J.
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 360 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115454	A2	20051208	WO 2005-US15981	20050509

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-569131P P 20040507

AB The present invention relates to compds. (e.g., peptidomimetics and non-peptides) that treat, prevent or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a BRCT domain-BACH1 phosphopeptide complex.

IT 183321-74-6, Erlotinib
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(X-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compns. for antitumor drug design)

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 21 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1242685 HCAPLUS
DOCUMENT NUMBER: 143:472533
TITLE: GST-activated anticancer therapy for sensitization or side effect amelioration of another anticancer
INVENTOR(S): Brown, Gail L.; Keck, James G.; Wick, Michael M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261202	A1	20051124	US 2005-133833	20050519
WO 2005112973	A1	20051201	WO 2005-US17960	20050519

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-572790P P 20040520
OTHER SOURCE(S): MARPAT 143:472533
GI



AB A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound I where L = cytotoxic electron withdrawing leaving group; Sx = -S(=O)-, -S(=O2)2-, -S(=NH)-, -S(=O)(=NH)-, etc.; R1, R2, and R3 is independently H or a noninterfering substituent; n = 0, 1, or 2; Y = H2NCH(COOH(CH2)m, HOOC(CH2)m, etc. (m = 1 or 2) and AA2 = amino acid

L4 ANSWER 21 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

linked by peptide bond). A method of ameliorating a side effect of another anticancer therapy in a mammal, esp. a human, by administering an ameliorating effective amt. of a GST-activated anticancer compd. Pharmaceutical compns. for the methods. The GST-activated anticancer compd. is preferably a compd. of U.S. Pat.No. 5,556,942, and more preferably canfosfamide, esp. as the hydrochloride salt.

IT 183319-69-9, Erlotinib hydrochloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GST-activated anticancer therapy for sensitization or side effect amelioration of another anticancer)

RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 22 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1004423 HCAPLUS
DOCUMENT NUMBER: 143:312080
TITLE: Artificial blood vessel for delivering therapeutic agents
INVENTOR(S): Bhat, Vinayak D.; Yan, John
PATENT ASSIGNEE(S): Avantec Vascular Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 206,807.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005203612	A1	20050915	US 2003-607836	20030627
US 2002082677	A1	20020627	US 2001-782804	20010213
US 7018405	B2	20060328		
US 2002114823	A1	20020822	US 2001-782927	20010213
US 6471980	B2	20021029		
US 2002082679	A1	20020627	US 2001-2595	20011101
US 2003083646	A1	20030501	US 2001-17500	20011214
US 7077859	B2	20060718		
US 2003050692	A1	20030313	US 2002-206807	20020725
US 2003017190	A1	20030123	US 2002-242334	20020911
US 6858221	B2	20050222		
WO 2004010900	A1	20040205	WO 2003-US20492	20030627

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003261100	A1	20040216	AU 2003-261100	20030627
JP 2005533604	T2	20051110	JP 2004-524538	20030627

PRIORITY APPLN. INFO.:
US 2000-258024P P 20001222
US 2001-782804 A2 20010213
US 2001-782927 A2 20010213
US 2001-783253 A2 20010213
US 2001-783254 A2 20010213
US 2001-308381P P 20010726
US 2001-2595 A2 20011101
US 2001-17500 A2 20011214
US 2002-347473P P 20020110
US 2002-355317P P 20020207
US 2002-370703P P 20020406
US 2002-206807 A2 20020725
US 2002-404624P P 20020819
US 2003-454146P P 20030311
US 2003-472536P P 20030521
WO 2003-US20492 W 20030627

AB Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for sustained or controlled release of at least one therapeutic capable agent

L4 ANSWER 22 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.
IT 183319-69-9, Tarceva
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(artificial blood vessel for delivering therapeutic agents)
RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 23 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:729564 HCAPLUS
DOCUMENT NUMBER: 143:186693
TITLE: Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
INVENTOR(S): Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072826	A2	20050811	WO 2005-US1710	20050120
WO 2005072826	A3	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005209231	A1	20050811	AU 2005-209231	20050120
PRIORITY APPLN. INFO.:			US 2004-537960P	P 20040121
			US 2004-553681P	P 20040316
			US 2004-614203P	P 20040929
			WO 2005-US1710	W 20050120

OTHER SOURCE(S): MARPAT 143:186693
AB Compns. and methods are provided for using tyrosine kinase inhibitors to treat pathogenic infection. In particular, methods for using Abl family tyrosine kinase inhibitors to treat pathogenic infection are provided. Infections to be treated according to the invention include, particularly, those caused by microbial pathogens such as bacteria and viruses.
IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tyrosine kinase inhibitors for treatment of pathogenic infection)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 24 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409543 HCAPLUS
DOCUMENT NUMBER: 142:457053
TITLE: Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy
INVENTOR(S): Lacasse, Eric; McManus, Daniel
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042558	A1	20050512	WO 2004-CA1902	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005148535	A1	20050707	US 2004-975974	20041028
CA 2542904	AA	20050512	CA 2004-2542904	20041029
EP 1682565	A1	20060726	EP 2004-789809	20041029
R: DE, FR, GB				
PRIORITY APPLN. INFO.:			US 2003-516192P	P 20031030
			WO 2004-CA1902	W 20041029

AB The invention provides nucleobase oligomers and oligonucleotide duplexes that inhibit expression of an IAP (inhibitor of apoptosis protein), and methods for using them to induce apoptosis in a cell. Specifically, the invention provides nucleic acid sequences for siRNAs and shRNAs that target human XIAP, HIAP-1 or HIAP-2 genes. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compns. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent. RNAi sequences and vectors producing shRNA (short hairpin RNA) were transfected into HeLa cells and evaluated for their effect on XIAP, cIAP-1, or cIAP-2 protein levels. XIAP protein could also be reduced by RNAi clones in transfected breast cancer cell line MDA-MB-231. In addition, cell survival was reduced in XIAP RNAi transfected breast cancer cell line after the transfected cells were treated with TRAIL (tumor necrosis factor-related apoptosis inducing ligand).
IT 183321-74-6, Erlotinib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)
RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 25 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:409357 HCAPLUS
DOCUMENT NUMBER: 142:457052
TITLE: Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent
INVENTOR(S): Lacasse, Eric; McManus, Daniel; Durkin, Jon P.
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042030	A1	20050512	WO 2004-CA1900	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005119217	A1	20050602	US 2004-975790	20041028
AU 2004284855	A1	20050512	AU 2004-284855	20041029
CA 2542884	AA	20050512	CA 2004-2542884	20041029
EP 1691842	A1	20060823	EP 2004-789807	20041029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-516263P P 20031030
WO 2004-CA1900 W 20041029

AB The invention claims the use of an antisense oligomer to human XIAP, IAP-1 or IAP-2 genes and a chemotherapeutic agent, and compns. and kits thereof, for the treatment of proliferative diseases. The invention further claims sequences for nucleobase oligomers that are antisense IAP (inhibitor of apoptosis protein) oligomers. The antisense IAP nucleobase oligomers specifically hybridize with polynucleotides encoding an IAP and reduce the amount of an IAP protein produced in a cell. Thus by reducing the IAP protein, the invention provides methods for inducing cancer cells to undergo apoptosis and for overriding anti-apoptotic signals in cancer cells. As an example of the invention, mice with s.c. H460 human lung carcinoma xenografts were injected intratumorally with XIAP antisense mixed-base 2'-O-Me RNA oligonucleotides (C5 and/or G4) and the drug vinorelbine. At the end of the 24 d treatment period, the mean relative tumor growth was reduced .apprx.70% in treated mice. The inhibition of tumor growth was correlated with down-regulation of human XIAP protein expression and an increased number of dead cells. The mice did not show any signs of cytotoxicity such as body weight loss.

IT 183321-74-6, Erlotinib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sequences of antisense IAP (inhibitor of apoptosis protein) oligomers

L4 ANSWER 25 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
and their use for treatment of proliferative diseases with chemotherapeutic agent)

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:283298 HCAPLUS
DOCUMENT NUMBER: 142:349042
TITLE: Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms
INVENTOR(S): Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027842	A2	20050331	WO 2004-US30368	20040916
WO 2005027842	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273910	A1	20050331	AU 2004-273910	20040916
CA 2538570	AA	20050331	CA 2004-2538570	20040916
EP 1670477	A2	20060621	EP 2004-788798	20040916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
NO 2006001325	A	20060606	NO 2006-1325	20060323

PRIORITY APPLN. INFO.: US 2003-504310P P 20030918
WO 2004-US30368 W 20040916

OTHER SOURCE(S): MARPAT 142:349042

AB The invention discloses a method for treating a patient having a cancer or other neoplasm by administering chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amts. sufficient to treat the patient.

IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorpromazine compound-antiproliferative drug antitumor combination)

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 27 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:216621 HCAPLUS
DOCUMENT NUMBER: 142:291341
TITLE: Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the PPAR-γ pathway and the HER kinase axis
INVENTOR(S): Agus, David B.; Jain, Anjali; Hedvat, Michael
PATENT ASSIGNEE(S): Cedars-Sinai Medical Center, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020923	A2	20050310	WO 2004-US28071	20040827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1658075	A2	20060524	EP 2004-782532	20040827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-498849P P 20030829
US 2004-568910P P 20040507
WO 2004-US28071 W 20040827

AB Methods are described for using a NSAID and a HER kinase axis inhibitor for the treatment of various conditions including cancer, and especially prostate, breast, lung, ovarian, brain and colon cancers, through regulation of PPARγ activity. In various embodiments, the NSAID and HER kinase axis inhibitor may be included in a composition that is useful for the treatment of conditions in a mammal. Also described is a kit including a NSAID and a HER kinase axis inhibitor along with instructions for use in treating and preventing disease conditions, e.g. cancer.

IT 183321-74-6, Erlotinib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and method for treatment of cancer and other conditions based on modulation of PPAR-γ pathway and HER kinase axis)

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 28 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:533970 HCAPLUS
DOCUMENT NUMBER: 141:65088
TITLE: Methods and compositions for the prevention or treatment of neoplasia comprising a COX-2 inhibitor in combination with an epidermal growth factor receptor antagonist
INVENTOR(S): Masferrer, Jaime
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 103 pp., Cont.-in-part of U.S. Ser. No. 470,951.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 21
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004127470	A1	20040701	US 2003-651916	20030829
EP 1522313	A1	20050413	EP 2004-26577	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY				
WO 2005037259	A2	20050428	WO 2004-US27574	20040825
WO 2005037259	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210578	A1	20041007	AU 2004-210578	20040910

PRIORITY APPLN. INFO.: US 1998-113786P P 19981223
US 1999-470951 B2 19991222
US 1999-385214 A 19990827
AU 2000-25936 A3 19991222
EP 1999-968939 A3 19991222
US 2003-651916 A 20030829

AB The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one COX-2 inhibitor in combination with an EGF receptor antagonist. Compns., pharmaceutical compns. and kits are also described.

IT 183319-69-9 183321-74-6, Erlotinib
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as EGFR antagonist; COX-2 inhibitor in combination with epidermal growth factor receptor antagonist for prevention or treatment of neoplasia)

RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
5,556,942, and more preferably TLK286, esp. as the hydrochloride salt.
IT 183319-69-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination cancer therapy with GST-activated anticancer compound and another anticancer therapy)
RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 29 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:453016 HCAPLUS
DOCUMENT NUMBER: 141:1227
TITLE: Combination cancer therapy with a glutathione S-transferase (GST)-activated anticancer compound and another anticancer therapy
INVENTOR(S): Xu, Hua; Brown, Gail L.; Schow, Steven R.; Keck, James G.
PATENT ASSIGNEE(S): Telik, Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045593	A2	20040603	WO 2003-US36209	20031114
WO 2004045593	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505377	AA	20040603	CA 2003-2505377	20031114
AU 2003290805	A1	20040615	AU 2003-290805	20031114
US 2004138140	A1	20040715	US 2003-714593	20031114
EP 1562564	A2	20050817	EP 2003-783388	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016364	A	20051004	BR 2003-16364	20031114
CN 1711076	A	20051221	CN 2003-80103404	20031114
JP 2006508980	T2	20060316	JP 2004-553614	20031114
PRIORITY APPLN. INFO.:			US 2002-426983P P	20021115
			WO 2003-US36209 W	20031114

OTHER SOURCE(S): MARPAT 141:1227
AB The invention discloses a method for combination cancer therapy in a mammal, especially a human, by administering a therapeutically effective amount of a GST-activated anticancer compound and a therapeutically ED of another anticancer therapy. Also disclosed are pharmaceutical compns., products, and kits for the method, as well as the use of a GST-activated anticancer compound in the manufacture of a medicament for the method. The invention further discloses a method for potentiating an anticancer therapy in a mammal, especially a human, comprising administering a therapeutically effective amount of a GST-activated anticancer compound to the mammal being treated with the anticancer therapy. Further disclosed is the use of a GST-activated anticancer compound in the manufacture of a medicament for the method. The GST-activated anticancer compound is preferably a compound of US Patent Number

L4 ANSWER 30 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41226 HCAPLUS
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491466	AA	20040115	CA 2003-2491466	20030709
AU 2003265264	A1	20040123	AU 2003-265264	20030709
US 2004077601	A1	20040422	US 2003-616694	20030709
US 2005084490	A1	20050421	US 2003-616409	20030709
EP 1578434	A2	20050928	EP 2003-763380	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T2	20060302	JP 2004-562634	20030709
CN 1802090	A	20060712	CN 2003-821282	20030709
CN 1826129	A	20060830	CN 2003-821281	20030709
PRIORITY APPLN. INFO.:			US 2002-394856P P	20020709
			US 2002-414978P P	20021001
			US 2003-466435P P	20030428
			WO 2003-US21405 W	20030709

OTHER SOURCE(S): MARPAT 140:105321
AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptioyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.
IT 183319-69-9, Tarceva
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or

L4 ANSWER 30 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
antigens)
RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 31 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:922829 HCAPLUS
DOCUMENT NUMBER: 140:280538
TITLE: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways
AUTHOR(S): Newton, Herbert B.
CORPORATE SOURCE: Dardinger Neuro-Oncology Center, Department of Neurology, Ohio State University Hospitals, Columbus, OH, 43210, USA
SOURCE: Expert Review of Anticancer Therapy (2003), 3(5), 595-614
CODEN: ERATBJ; ISSN: 1473-7140
PUBLISHER: Future Drugs Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Brain tumors are a diverse group of malignancies that remain refractory to conventional treatment approaches, including radiotherapy and cytotoxic chemotherapy. Mol. neuro-oncol. has now begun to clarify the transformed phenotype of brain tumors and identify oncogenic pathways that may be amenable to targeted therapy. Growth factor signaling pathways are often upregulated in brain tumors and may contribute to oncogenesis through autocrine and paracrine mechanisms. Excessive growth factor receptor stimulation can also lead to overactivity of the Ras signaling pathway, which is frequently aberrant in brain tumors. Receptor tyrosine kinase inhibitors, antireceptor monoclonal antibodies and antisense oligonucleotides are targeted approaches under investigation as methods to regulate aberrant growth factor signaling pathways in brain tumors. Several receptor tyrosine kinase inhibitors, including imatinib mesylate (Gleevec), gefitinib (Iressa) and erlotinib (Tarceva), have entered clin. trials for high-grade glioma patients. Farnesyl transferase inhibitors, such as tipifarnib (Zarnestra), which impair processing of proRas and inhibit the Ras signaling pathway, have also entered clin. trials for patients with malignant gliomas. Further development of targeted therapies and evaluation of these new agents in clin. trials will be needed to improve survival and quality of life of patients with brain tumors.
IT 183319-69-9, Tarceva
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. therapeutics targeting growth factor and Ras signaling pathways in brain tumors)
RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:355612 HCAPLUS
DOCUMENT NUMBER: 138:362649
TITLE: Treatment of cancer with anti-ErbB2 antibodies
INVENTOR(S): Sliwkowski, Mark X.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 602,812.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003086924	A1	20030508	US 2002-268501	20021010
US 6949245	B1	20050927	US 2000-602812	20000623
US 2004013667	A1	20040122	US 2003-608626	20030627
US 2005208043	A1	20050922	US 2005-44749	20050127
US 2005238640	A1	20051027	US 2005-154465	20050616
US 2006034842	A1	20060216	US 2005-223361	20050909
US 2006073143	A1	20060406	US 2005-222587	20050909
AU 2005242195	A1	20060112	AU 2005-242195	20051207
US 2006193854	A1	20060831	US 2006-429361	20060505
US 2006198843	A1	20060907	US 2006-429043	20060505
PRIORITY APPLN. INFO.:			US 1999-141316P	P 19990625
			US 2000-602812	A2 20000623
			AU 2000-57632	A3 20000623
			US 2002-268501	A2 20021010
			US 2005-44749	A1 20050127

AB The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor. Recombinant humanized monoclonal antibody 2C4 was effective in inhibiting breast cancer tumor growth in MCF7 xenografts.
IT 183319-69-9, CP 358774
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as EGFR targeted drug in combination with anti-ErbB2 antibodies; cancer treatment with anti-ErbB2 antibodies)
RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

L4 ANSWER 33 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:489208 HCAPLUS
DOCUMENT NUMBER: 135:97443
TITLE: Pharmaceutical compositions containing polymer for enhanced drug concentrations
INVENTOR(S): Babcock, Walter Christian; Curatolo, William John; Friesen, Dwayne Thomas; Lorenz, Douglas Alan; Nightingale, James Alan Schriver; Shanker, Ravi Mysore
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047495	A1	20010705	WO 2000-IB1787	20001201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US. UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395331	AA	20010705	CA 2000-2395331	20001201
BR 2000016555	A	20020917	BR 2000-16555	20001201
EP 1239835	A1	20020918	EP 2000-976217	20001201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200201617	T2	20021021	TR 2002-1617	20001201
JP 2003518485	T2	20030610	JP 2001-548090	20001201
EE 200200357	A	20031015	EE 2002-357	20001201
AU 784340	B2	20060316	AU 2001-14091	20001201
US 2002006443	A1	20020117	US 2000-742785	20001220
BG 106764	A	20030331	BG 2002-106764	20020531
ZA 2002004962	A	20030929	ZA 2002-4962	20020620
NO 2002002998	A	20020815	NO 2002-2998	20020621
PRIORITY APPLN. INFO.:			US 1999-171841P	P 19991223
			WO 2000-IB1787	W 20001201

AB A drug in a solubility-improved form is combined with a concentration-enhancing polymer, i.e., a cellulosic or non-cellulosic polymer, in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment,, such as digestive tract, s.c. space, vagina, lung, blood vessels, and muscle relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer. For example, the solubility of sertraline-HCl was increased in presence of citric acid, giving a solubility-improvement factor of 9.3. Thus, citric acid is an excellent solubilizing agent for sertraline-HCl. A solution was prepared containing 1000 μg/mL sertraline-HCl, 500 μg/mL citric

L4 ANSWER 33 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

acid, and 1000 μg/mL hydroxypropyl Me cellulose acetate succinate (HPMCAS) in phosphate buffer. (pH 7.9). Addn. of the concn.-enhancing polymer HPMCAS resulted in a max. concn. that was 1.7-fold that of control contg. no polymer.

IT 248594-19-6
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical compns. containing polymer for enhanced drug concns.)

RN 248594-19-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 183321-74-6
CMF C22 H23 N3 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:832615 HCAPLUS
DOCUMENT NUMBER: 134:178249
TITLE: Discovery of a new stable polymorph of 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form change kinetics
AUTHOR(S): Norris, Timothy; Santafianos, Dinos
CORPORATE SOURCE: Pfizer Global Research and Development Laboratories, Groton, CT, 06340, USA
SOURCE: Perkin 2 (2000), (12), 2498-2502
CODEN: PRKTFO; ISSN: 1470-1820
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Polymorphism is an important property of crystalline organic mols., particularly when used to develop medicines. Discovery of all the polymorphs in a series is often difficult. This paper highlights the use of near-IR spectroscopy to monitor the kinetics of form changes of polymorphs and solvates (hydrates). In the case of mesylate salt 5, this led to the discovery of a new preferred form. Identification and confirmation of unique polymorph crystal states are determined using x-ray powder diffraction patterns. This complements and confirms the kinetic change observed in the near-IR. The technique is generally applicable to the study of two-phase solid-liquid crystal slurries under isothermal conditions.

IT 183321-74-6
RL: FMU (Formation, unclassified); RCT (Reactant); FORM (Formation, nonpreparative); RACT (Reactant or reagent)
(free base; near-IR examination of form change kinetics and stable polymorph of 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazolinium methanesulfonate)

RN 183321-74-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



IT 183319-69-9P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(ion exchange; near-IR examination of form change kinetics and stable polymorph of 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazolinium methanesulfonate)

RN 183319-69-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

IT 248594-19-6P 248594-20-9P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(near-IR examination of form change kinetics and stable polymorph of 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazolinium methanesulfonate)

RN 248594-19-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 183321-74-6
CMF C22 H23 N3 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

L4 ANSWER 34 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 248594-20-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monomethanesulfonate, monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 183321-74-6
CMF C22 H23 N3 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:708748 HCAPLUS
DOCUMENT NUMBER: 131:327542
TITLE: N-(3-Ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
INVENTOR(S): Allen, Douglas John Meldrum; Norris, Timothy; Raggon, Jeffrey William; Santafianos, Dinos Paul; Shanker, Ravi Mysore
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955683	A1	19991104	WO 1999-IB612	19990408
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2330447	AA	19991104	CA 1999-2330447	19990408
AU 9928509	A1	19991116	AU 1999-28509	19990408
AU 759691	B2	20030417		
BR 9910025	A	20001226	BR 1999-10025	19990408
EP 1076652	A1	20010221	EP 1999-909165	19990408
EP 1076652	B1	20050518		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 200003166	T2	20010221	TR 2000-200003166	19990408
JP 2002513009	T2	20020508	JP 2000-545843	19990408
NZ 508154	A	20030725	NZ 1999-508154	19990408
AT 295839	E	20050615	AT 1999-909165	19990408
ES 2238825	T3	20050901	ES 1999-909165	19990408
ZA 9902972	A	20001030	ZA 1999-2972	19990428
AP 1252	A	20040225	AP 1999-1523	19990429
W: BW, GH, GM, KE, MW, SD, UG, ZM, ZW				
US 6706721	B1	20040316	US 1999-355534	19990729
NO 2000005453	A	20001220	NO 2000-5453	20001027
NO 317301	B1	20041004		
HK 1037180	A1	20051028	HK 2001-105821	20010817
US 2004102463	A1	20040527	US 2003-716098	20031117

PRIORITY APPLN. INFO.:
US 1998-83441P P 19980429
WO 1999-IB612 W 19990408
US 1999-355534 A1 19990729

AB The title compound, an inhibitor of erbB protein tyrosine kinases useful in treatment of hyperproliferative disorders such as cancer, can exist in 3 anhydrous polymorphic forms (A, B, and C) and as a monohydrate, which are all interconvertible. These isoforms are characterized by their x-ray powder diffraction patterns.

IT 248594-19-6 248594-20-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
((Ethynylphenylamino)bis(methoxyethoxy)quinazolinamine mesylate anhydrate and monohydrate)

RN 248594-19-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 183321-74-6
CMF C22 H23 N3 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 248594-20-9 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monomethanesulfonate, monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 183321-74-6
CMF C22 H23 N3 O4

L4 ANSWER 35 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT